Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lacer SafiledCriticalLacer Sa
Publication of AR064544A1publicationCriticalpatent/AR064544A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente se refiere al uso de un compuesto de formula (1) o un tautomero, una sal farmacéuticamente aceptable, un profármaco o un solvato del mismo, como ingrediente o ingredientes activos en la fabricacion de una composicion farmacéutica para la prevencion y/o tratamiento de enfermedades oftalmologicas mediadas por hipertension ocular.This refers to the use of a compound of formula (1) or a tautomer, a pharmaceutically acceptable salt, a prodrug or a solvate thereof, as an active ingredient or ingredients in the manufacture of a pharmaceutical composition for the prevention and / or treatment of ophthalmological diseases mediated by ocular hypertension.
ARP0701059122006-12-282007-12-27
USE OF DIANHYDROHEXITE MONONITRATE DERIVATIVES AS REDUCING AGENTS OF OCULAR HYPERTENSION
AR064544A1
(en)
HYDROCLORIDE OF (4- (5-AMINOMETIL-2-FLUORO-PHENYL) -PIPERIDIN-1-IL) - (4-BROMO-3-METHYL-5-PROPOXI-TIOFEN-2-IL) -METANONE AS AN INHIBITOR OF THE MASTOCYT TRIPTASE
DERIVATIVES OF 6-HYDROXY-INDAZOL, AN OPHTHALMIC COMPOSITION, AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF GLAUCOMA